AI
Sunday, December 17, 2017 4:45:19 AM
MRNS is testing the IV version of ganaxolone in PPD so your conclusion is obviously wrong. No results were ever presented with the IV version. Before they tested an oral version. Bioavailibility should be much better with the IV version.
Also the MDD study you are refering to is not a study conducted by MRNS. Why blame them?
I think MRNS is a high risk bet but the points you made are both misleading. And yes - there is a chance
Also the MDD study you are refering to is not a study conducted by MRNS. Why blame them?
I think MRNS is a high risk bet but the points you made are both misleading. And yes - there is a chance
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
